The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Abstract
The clinical development of an inhibitor of cellular proteasome function suggests that compounds targeting other components of the ubiquitin-proteasome system might prove useful for the treatment of human malignancies. NEDD8-activating enzyme (NAE) is an essential component of the NEDD8 conjugation pathway that controls the activity of the cullin-RING subtype of ubiquitin ligases, thereby regulating the turnover of a subset of proteins upstream of the proteasome. Substrates of cullin-RING ligases have important roles in cellular processes associated with cancer cell growth and survival pathways. Here we describe MLN4924, a potent and selective inhibitor of NAE. MLN4924 disrupts cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumour cells by a new mechanism of action, the deregulation of S-phase DNA synthesis. MLN4924 suppressed the growth of human tumour xenografts in mice at compound exposures that were well tolerated. Our data suggest that NAE inhibitors may hold promise for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“orthogonally confirmed dose-dependent KAT2A degradation by western blot, and demonstrated that this degradation can be rescued by pre-treatment with a UBA3/NAE1 inhibitor, MLN4924 (37), a proteasome inhibitor, bortezomib (38), and a competing CRBN ligand, pomalidomide (7) (Fig. 1D).”
From Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues (2026) · cites this paper as [37]
In the citing paper
“we cotreated cells with a proteasome inhibitor (bortezomib) or a NEDD8-activating enzyme E1 inhibitor (MLN-4924 32 ) and found that both inhibitors prevented degradation of BTK (Figure 2D).”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [32]
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Self-citationKobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
Carrano, A. C., Eytan, E., Hershko, A., & Pagano, M. (1999) · Nature Cell Biology · doi:10.1038/12013 · Cited by 1,543
Modification of Proteins by Ubiquitin and Ubiquitin-Like Proteins
Kerscher, O., Felberbaum, R., & Hochstrasser, M. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010605.093503 · Cited by 1,517
Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J., & Harper, J. W. (1999) · Genes & Development · doi:10.1101/gad.13.3.270 · Cited by 954
Duda, D. M., Borg, L. A., Scott, D. C., Hunt, H. W., Hammel, M., & Schulman, B. A. (2008) · Cell · doi:10.1016/j.cell.2008.07.022 · Cited by 767
Kamura, T., Sato, S., Iwai, K., Czyzyk-Krzeska, M., Conaway, R. C., & Conaway, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190332597 · Cited by 653
Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy
Kane, R. C., Bross, P. F., Farrell, A. T., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-6-508 · Cited by 628
Cited by
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo Arozena, A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., et al. (2016) · Autophagy · doi:10.1080/15548627.2015.1100356 · Cited by 5,894
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., Abel, S., Abeliovich, H., Abildgaard, M. H., Abudu, Y. P., Acevedo-Arozena, A., et al. (2021) · Autophagy · doi:10.1080/15548627.2020.1797280 · Cited by 2,897
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway
Baird, L., & Yamamoto, M. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00099-20 · Cited by 1,542
Systematic and Quantitative Assessment of the Ubiquitin-Modified Proteome
Kim, W., Bennett, E. J., Huttlin, E. L., Guo, A., Li, J., Possemato, A., Sowa, M. E., Rad, R., Rush, J., Comb, M. J., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.025 · Cited by 1,613
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Ubiquitination in disease pathogenesis and treatment
Popovic, D., Vucic, D., & Dikic, I. (2014) · Nature Medicine · doi:10.1038/nm.3739 · Cited by 1,401
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Self-citationBuilding ubiquitin chains: E2 enzymes at work
Ye, Y., & Rape, M. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2780 · Cited by 989
Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways
Schulman, B. A., & Wade Harper, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2673 · Cited by 943
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Chen, D., Frezza, M., Schmitt, S., Kanwar, J., & P. Dou, Q. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519752 · Cited by 795
Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D. (2017) · Science · doi:10.1126/science.aal3755 · Cited by 762
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.009 · Cited by 686
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
Protein neddylation: beyond cullin–RING ligases
Enchev, R. I., Schulman, B. A., & Peter, M. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3919 · Cited by 615
Lenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor
Decorsière, A., Mueller, H., van Breugel, P. C., Abdul, F., Gerossier, L., Beran, R. K., Livingston, C. M., Niu, C., Fletcher, S. P., Hantz, O., et al. (2016) · Nature · doi:10.1038/nature17170 · Cited by 551
Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., & Brownell, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3321 · Cited by 563
“Studies using NF-κB-dependent human cancer models have demonstrated increased levels of the CRL1β TRCP substrate pIκBα and inhibition of NF-κB activity and apoptosis 116, 117 , suggesting the feasibility of NAE inhibition for the treatment of disease that is associated with constitutively active NF-κB signalling 112 T…”
MethodSelf-citationBAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-Oezguer, J., Riedmueller, C., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0294-6 · Cited by 562
Sarikas, A., Hartmann, T., & Pan, Z.-Q. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-220 · Cited by 522
Radhakrishnan, S. K., Lee, C. S., Young, P., Beskow, A., Chan, J. Y., & Deshaies, R. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.02.029 · Cited by 526
The Cullin-RING Ubiquitin-Protein Ligases
Hua, Z., & Vierstra, R. D. (2011) · Annual Review of Plant Biology · doi:10.1146/annurev-arplant-042809-112256 · Cited by 511
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08027-7 · Cited by 517
Zhao, J., Zhai, B., Gygi, S. P., & Goldberg, A. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521919112 · Cited by 484
Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
Zhang, X., Crowley, V. M., Wucherpfennig, T. G., Dix, M. M., & Cravatt, B. F. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0279-5 · Cited by 487
Staudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485
Brownell, J. E., Sintchak, M. D., Gavin, J. M., Liao, H., Bruzzese, F. J., Bump, N. J., Soucy, T. A., Milhollen, M. A., Yang, X., Burkhardt, A. L., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2009.12.024 · Cited by 464
Self-citationPathogenesis of Human B Cell Lymphomas
Shaffer, A. L., Young, R. M., & Staudt, L. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075027 · Cited by 437
Targeted Degradation of Oncogenic KRAS G12C by VHL-Recruiting PROTACs
Bond, M. J., Chu, L., Nalawansha, D. A., Li, K., & Crews, C. M. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00411 · Cited by 450
A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment
Hyer, M. L., Milhollen, M. A., Ciavarri, J., Fleming, P., Traore, T., Sappal, D., Huck, J., Shi, J., Gavin, J., Brownell, J., et al. (2018) · Nature Medicine · doi:10.1038/nm.4474 · Cited by 447
Self-citationThe ubiquitin‐proteasome system regulates plant hormone signaling
Santner, A., & Estelle, M. (2010) · The Plant Journal · doi:10.1111/j.1365-313x.2010.04112.x · Cited by 429
Perilous journey: a tour of the ubiquitin–proteasome system
Kleiger, G., & Mayor, T. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.12.003 · Cited by 409
Ubiquitin–proteasome system (UPS) as a target for anticancer treatment
Park, J., Cho, J., & Song, E. J. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01281-8 · Cited by 408
Drugging the undruggables: exploring the ubiquitin system for drug development
Huang, X., & Dixit, V. M. (2016) · Cell Research · doi:10.1038/cr.2016.31 · Cited by 427
CRL4s: the CUL4-RING E3 ubiquitin ligases
Jackson, S., & Xiong, Y. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.07.002 · Cited by 411
Shelton, J., Lu, X., Hollenbaugh, J. A., Cho, J. H., Amblard, F., & Schinazi, R. F. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00209 · Cited by 409
Global Identification of Modular Cullin-RING Ligase Substrates
Emanuele, M. J., Elia, A. E. H., Xu, Q., Thoma, C. R., Izhar, L., Leng, Y., Guo, A., Chen, Y.-N., Rush, J., Hsu, P. W.-C., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.019 · Cited by 404
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence
Lin, H.-K., Chen, Z., Wang, G., Nardella, C., Lee, S.-W., Chan, C.-H., Yang, W.-L., Wang, J., Egia, A., Nakayama, K. I., et al. (2010) · Nature · doi:10.1038/nature08815 · Cited by 400
Selective degradation of splicing factor CAPERα by anticancer sulfonamides
Uehara, T., Minoshima, Y., Sagane, K., Sugi, N. H., Mitsuhashi, K. O., Yamamoto, N., Kamiyama, H., Takahashi, K., Kotake, Y., Uesugi, M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2363 · Cited by 396
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., O’Meara, M. J., Guo, J. Z., Swaney, D. L., Tummino, T. A., Huettenhain, R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.22.002386 · Cited by 395
Chan, C.-H., Morrow, J. K., Li, C.-F., Gao, Y., Jin, G., Moten, A., Stagg, L. J., Ladbury, J. E., Cai, Z., Xu, D., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.048 · Cited by 391
The demographics of the ubiquitin system
Clague, M. J., Heride, C., & Urbé, S. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.03.002 · Cited by 373
Dynamics of Cullin-RING Ubiquitin Ligase Network Revealed by Systematic Quantitative Proteomics
Bennett, E. J., Rush, J., Gygi, S. P., & Harper, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.11.017 · Cited by 386
van der Veen, A. G., & Ploegh, H. L. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-093010-153308 · Cited by 361
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Short, N. J., Konopleva, M., Kadia, T. M., Borthakur, G., Ravandi, F., DiNardo, C. D., & Daver, N. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1011 · Cited by 368
Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases
Eltzschig, H. K., Bratton, D. L., & Colgan, S. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4422 · Cited by 366
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches
Liu, F., Chen, J., Li, K., Li, H., Zhu, Y., Zhai, Y., Lu, B., Fan, Y., Liu, Z., Chen, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02046-3 · Cited by 326
SCF ubiquitin ligase-targeted therapies
Skaar, J. R., Pagan, J. K., & Pagano, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4432 · Cited by 335
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy
Deshaies, R. J. (2014) · BMC Biology · doi:10.1186/s12915-014-0094-0 · Cited by 337
Zoppi, V., Hughes, S. J., Maniaci, C., Testa, A., Gmaschitz, T., Wieshofer, C., Koegl, M., Riching, K. M., Daniels, D. L., Spallarossa, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01413 · Cited by 336
The Eukaryotic Proteome Is Shaped by E3 Ubiquitin Ligases Targeting C-Terminal Degrons
Koren, I., Timms, R. T., Kula, T., Xu, Q., Li, M. Z., & Elledge, S. J. (2018) · Cell · doi:10.1016/j.cell.2018.04.028 · Cited by 323
Building and remodelling Cullin–RING E3 ubiquitin ligases
Lydeard, J. R., Schulman, B. A., & Harper, J. W. (2013) · The EMBO Reports · doi:10.1038/embor.2013.173 · Cited by 327
Regulation of NF‐κB by ubiquitination and degradation of the IκBs
Kanarek, N., & Ben‐Neriah, Y. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01098.x · Cited by 324
Milhollen, M. A., Traore, T., Adams-Duffy, J., Thomas, M. P., Berger, A. J., Dang, L., Dick, L. R., Garnsey, J. J., Koenig, E., Langston, S. P., et al. (2010) · Blood · doi:10.1182/blood-2010-03-272567 · Cited by 323
Self-citationInhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
Pfister, S. X., Markkanen, E., Jiang, Y., Sarkar, S., Woodcock, M., Orlando, G., Mavrommati, I., Pai, C.-C., Zalmas, L.-P., Drobnitzky, N., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.015 · Cited by 300
The KEAP1-NRF2 pathway: Targets for therapy and role in cancer
Adinolfi, S., Patinen, T., Jawahar Deen, A., Pitkänen, S., Härkönen, J., Kansanen, E., Küblbeck, J., & Levonen, A.-L. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102726 · Cited by 292
Buisson, R., Boisvert, J. L., Benes, C. H., & Zou, L. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.029 · Cited by 316
Cancer Selective Target Degradation by Folate-Caged PROTACs
Liu, J., Chen, H., Liu, Y., Shen, Y., Meng, F., Kaniskan, H. Ü., Jin, J., & Wei, W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00451 · Cited by 297
Exploiting replicative stress to treat cancer
Dobbelstein, M., & Sørensen, C. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4553 · Cited by 302
COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics
Yesudhas, D., Srivastava, A., & Gromiha, M. M. (2021) · Infection · doi:10.1007/s15010-020-01516-2 · Cited by 270
Bioactive iridium and rhodium complexes as therapeutic agents
Leung, C.-H., Zhong, H.-J., Chan, D. S.-H., & Ma, D.-L. (2013) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2013.01.034 · Cited by 303
SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer
Eifler, K., & Vertegaal, A. C. O. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.09.006 · Cited by 290
Degradation of the antiviral component ARGONAUTE1 by the autophagy pathway
Derrien, B., Baumberger, N., Schepetilnikov, M., Viotti, C., De Cillia, J., Ziegler-Graff, V., Isono, E., Schumacher, K., & Genschik, P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209487109 · Cited by 292
Lin, J. J., Milhollen, M. A., Smith, P. G., Narayanan, U., & Dutta, A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2062 · Cited by 292
Self-citationSmall-Molecule Modulation of Protein Homeostasis
Burslem, G. M., & Crews, C. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00077 · Cited by 283
Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands
Remillard, D., Buckley, D. L., Paulk, J., Brien, G. L., Sonnett, M., Seo, H., Dastjerdi, S., Wühr, M., Dhe‐Paganon, S., Armstrong, S. A., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611281 · Cited by 288
Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Bose, P., Dai, Y., & Grant, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.04.004 · Cited by 280
Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy
Wang, W., Nag, S., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106124315 · Cited by 282
The molecular pathology of cancer
Harris, T. J. R., & McCormick, F. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.41 · Cited by 276
Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases?
Cohen, P., & Tcherpakov, M. (2010) · Cell · doi:10.1016/j.cell.2010.11.016 · Cited by 271
Cullin-RING Ligases as Attractive Anti-cancer Targets
Zhao, Y., & Sun, Y. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990300 · Cited by 278
Bassermann, F., Eichner, R., & Pagano, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.02.028 · Cited by 268
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
Swords, R. T., Kelly, K. R., Smith, P. G., Garnsey, J. J., Mahalingam, D., Medina, E., Oberheu, K., Padmanabhan, S., O'Dwyer, M., Nawrocki, S. T., et al. (2010) · Blood · doi:10.1182/blood-2009-11-254862 · Cited by 274
Self-citationZhao, Y., Xiong, X., & Sun, Y. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.029 · Cited by 272
NEDD8 nucleates a multivalent cullin–RING–UBE2D ubiquitin ligation assembly
Baek, K., Krist, D. T., Prabu, J. R., Hill, S., Klügel, M., Neumaier, L.-M., von Gronau, S., Kleiger, G., & Schulman, B. A. (2020) · Nature · doi:10.1038/s41586-020-2000-y · Cited by 270
Control and dysregulation of redox signalling in the gastrointestinal tract
Campbell, E. L., & Colgan, S. P. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0079-5 · Cited by 251
Cullin-RING Ubiquitin Ligase Regulatory Circuits: A Quarter Century Beyond the F-Box Hypothesis
Harper, J. W., & Schulman, B. A. (2021) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-090120-013613 · Cited by 256
Irreversible APC Cdh1 Inactivation Underlies the Point of No Return for Cell-Cycle Entry
Cappell, S. D., Chung, M., Jaimovich, A., Spencer, S. L., & Meyer, T. (2016) · Cell · doi:10.1016/j.cell.2016.05.077 · Cited by 240
Neddylation: a novel modulator of the tumor microenvironment
Zhou, L., Jiang, Y., Luo, Q., Li, L., & Jia, L. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0979-1 · Cited by 249
Frost, J., Galdeano, C., Soares, P., Gadd, M. S., Grzes, K. M., Ellis, L., Epemolu, O., Shimamura, S., Bantscheff, M., Grandi, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms13312 · Cited by 239
The ZSWIM8 ubiquitin ligase mediates target-directed microRNA degradation
Shi, C. Y., Kingston, E. R., Kleaveland, B., Lin, D. H., Stubna, M. W., & Bartel, D. P. (2020) · Science · doi:10.1126/science.abc9359 · Cited by 236
Maniaci, C., Hughes, S. J., Testa, A., Chen, W., Lamont, D. J., Rocha, S., Alessi, D. R., Romeo, R., & Ciulli, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00954-1 · Cited by 245
Jung, A. C., Briolat, J., Millon, R., de Reyniès, A., Rickman, D., Thomas, E., Abecassis, J., Clavel, C., & Wasylyk, B. (2010) · International Journal of Cancer · doi:10.1002/ijc.24911 · Cited by 237
Targeted protein degradation for cancer therapy
Hinterndorfer, M., Spiteri, V. A., Ciulli, A., & Winter, G. E. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-025-00817-8 · Cited by 210
Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy
Zhao, Y., Morgan, M. A., & Sun, Y. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5795 · Cited by 238
A glycine-specific N-degron pathway mediates the quality control of protein N -myristoylation
Timms, R. T., Zhang, Z., Rhee, D. Y., Harper, J. W., Koren, I., & Elledge, S. J. (2019) · Science · doi:10.1126/science.aaw4912 · Cited by 240
(2012) · doi:10.1158/0008-5472.can-12-0388 · Cited by 242
An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme
Ceccarelli, D. F., Tang, X., Pelletier, B., Orlicky, S., Xie, W., Plantevin, V., Neculai, D., Chou, Y.-C., Ogunjimi, A., Al-Hakim, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.05.039 · Cited by 235
The ubiquitous role of ubiquitin in the DNA damage response
Al-Hakim, A., Escribano-Diaz, C., Landry, M.-C., O’Donnell, L., Panier, S., Szilard, R. K., & Durocher, D. (2010) · DNA Repair · doi:10.1016/j.dnarep.2010.09.011 · Cited by 223
Swords, R. T., Erba, H. P., DeAngelo, D. J., Bixby, D. L., Altman, J. K., Maris, M., Hua, Z., Blakemore, S. J., Faessel, H., Sedarati, F., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13323 · Cited by 231
Bulatov, E., & Ciulli, A. (2015) · Biochemical Journal · doi:10.1042/bj20141450 · Cited by 237
de Wispelaere, M., Du, G., Donovan, K. A., Zhang, T., Eleuteri, N. A., Yuan, J. C., Kalabathula, J., Nowak, R. P., Fischer, E. S., Gray, N. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11429-w · Cited by 237
Ubiquitination of DNA Damage-Stalled RNAPII Promotes Transcription-Coupled Repair
Nakazawa, Y., Hara, Y., Oka, Y., Komine, O., van den Heuvel, D., Guo, C., Daigaku, Y., Isono, M., He, Y., Shimada, M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.010 · Cited by 236
Crystal structure of the human COP9 signalosome
Lingaraju, G. M., Bunker, R. D., Cavadini, S., Hess, D., Hassiepen, U., Renatus, M., Fischer, E. S., & Thomä, N. H. (2014) · Nature · doi:10.1038/nature13566 · Cited by 227
Targeting tumour-supportive cellular machineries in anticancer drug development
Dobbelstein, M., & Moll, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4201 · Cited by 229
Metadata
- Authors
- Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., Cullis, C. A., Doucette, A., Garnsey, J. J., Gaulin, J. L., Gershman, R. E., Lublinsky, A. R., McDonald, A., Mizutani, H., Narayanan, U., Olhava, E. J., Peluso, S., Rezaei, M., Sintchak, M. D., Talreja, T., Thomas, M. P., Traore, T., Vyskocil, S., Weatherhead, G. S., Yu, J., Zhang, J., Dick, L. R., Claiborne, C. F., Rolfe, M., Bolen, J. B., & Langston, S. P.
- Affiliations
- Takeda Oncology (United States) (US)
- Corresponding author
- Soucy, Teresa A.
- ORCID
- Venue
- Nature
- Published
- 2009-04
- Volume
- 458
- Issue
- 7239
- Pages
- 732-736
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2076194625
- Cited by
- 1,990
- References
- 46
- Citations by year
- 2026: 110 · 2025: 120 · 2024: 156 · 2023: 126 · 2022: 137 · 2021: 155 · 2020: 170 · 2019: 149 · 2018: 112 · 2017: 105 · 2016: 108 · 2015: 98 · 2014: 99 · 2013: 100 · 2012: 100
- FWCI
- 32.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- NEDD8-activating enzyme, MLN4924, cullin-RING ubiquitin ligases, ubiquitin-proteasome system, proteasome inhibitors, cancer cell death, tumor xenografts, small molecule inhibitors, antitumour activity
- MeSH terms
- NEDD8 Protein, Animals, Antineoplastic Agents, Cells, Cultured, Cyclopentanes, Enzyme Inhibitors, Female, Humans, Neoplasms, Pyrimidines, Transplantation, Heterologous, Ubiquitins, Ubiquitin-Activating Enzymes, Cullin Proteins, Cell Line, Tumor, Mice, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.